NDRA - הכנסה תפעולית לפני ניכוי פחת ENDRA Life Sciences Inc

Leveraging the human capital of non-invasive analysis engineers, ENDRA Life Sciences (NDRA) is developing an R&D culture. The EBITDA metric demonstrates current operational efficiency, where the value of 0.00 characterizes this level. The strategy is based on integrating TAEUS technology into ultrasound machines as an affordable alternative to MRI, while the innovation roadmap is focused on the commercial launch of a fatty liver disease assessment system.

The fabless model of ENDRA Life Sciences (NDRA), utilizing assembly outsourcing within the US, converts primary costs into variable expenses, rendering actual operating profit a precise indicator of technology commercialization efficiency. This metric measures the real cash inflow from core operations before depreciation and taxes, allowing investors to filter out market noise and determine the true resilience of the business through the analysis of this chart.